Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 continuation study of MT1621 in thymidine kinase 2 deficiency
MOH_2019-03-31_006059Phase 2Not yet recruiting
- Sponsor
- Modis Therapeutics
- Start
- Mar 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT1621, 2'-deoxycytidine and doxribtimine in thymidine kinase 2 deficiency (TK2D), sponsored by Modis Therapeutics. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
MT16212'-deoxycytidinedoxribtimine
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on MOH_2019-03-31_006059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-31_006059.